Use your antibodies-online credentials, if available.
抗Mouse (Murine) LMO1 抗体:
抗Rat (Rattus) LMO1 抗体:
抗Human LMO1 抗体:
SCL (显示 TAL1 抗体)-LMO1 upregulated a stem cell gene signature in DN3 thymocytes.
Loss of Lmo1 repression may be one of the causes accounting for the phenotypic differences identified between the Arx((GCG)7)and Arx(432-455dup24) mouse models.
SCL (显示 TAL1 抗体), LMO1, and Notch1 (显示 NOTCH1 抗体) gain of function, together with an active pre-T-cell antigen receptor (显示 PTCRA 抗体), might represent the minimum set of complementing events for the transformation of susceptible thymocytes into cancer cells
Results suggest that all four members of the LIM (显示 PDLIM5 抗体)-only family -- LMO1, 2, 3, and 4 -- are important regulators of distinct developmental pathways.
Lmo1 takes part in a Hox (显示 MSH2 抗体) paralogue 2-dependent network regulating anteroposterior and dorsoventral hindbrain patterning
A C-to-T single nucleotide transition occurs as a somatic mutation in noncoding sequences 4 kb upstream of the transcriptional start site of the LMO1 oncogene (显示 RAB1A 抗体) in primary samples from patients with T-cell acute lymphoblastic leukaemia. This conforms to an APOBEC-like cytidine deaminase (显示 CDA 抗体) mutational signature and a new MYB (显示 MYB 抗体) binding site driving high levels of LMO1 expression.
LMO1 is an important oncogene (显示 RAB1A 抗体) that promotes neuroblastoma (显示 ARHGEF16 抗体) initiation, progression, and widespread metastatic dissemination.
LMO1 appears to be a coactivator of AR involved in the progression of prostate cancer
data suggest that genetic variants in LMO1 are associated with increased NB risk in Chinese children.
a polymorphism within a super-enhancer element in the first intron of LMO1 influences neuroblastoma (显示 ARHGEF16 抗体) susceptibility through differential GATA (显示 QRSL1 抗体) transcription factor binding and direct modulation of LMO1 expression in cis (显示 CISH 抗体)
LMO1 is a commonly activated tumor promoter that activates AKT (显示 AKT1 抗体) signaling in non-small cell lung cancer.
LMO1 is a commonly activated tumor promoter that activates AKT (显示 AKT1 抗体) signaling in colorectal cancer and a new predictive marker for targeted therapy.
results show that LMO1 is poised for expression in normal progenitors, where activation of SCL/TAL1 (显示 TAL1 抗体) together with a breakdown of epigenetic repression of LMO1 regulatory elements
genetic variants within LMO1 are associated with acute lymphoblastic leukemia and identify this gene as a strong candidate for precursor B-cell leukemogenesis.
data show that common polymorphisms at the LMO1 locus are strongly associated with susceptibility to developing neuroblastoma (显示 ARHGEF16 抗体), but also may influence the likelihood of further somatic alterations at this locus, leading to malignant progression
This locus encodes a transcriptional regulator that contains two cysteine-rich LIM domains but lacks a DNA-binding domain. LIM domains may play a role in protein interactions\; thus the encoded protein may regulate transcription by competitively binding to specific DNA-binding transcription factors. Alterations at this locus have been associated with acute lymphoblastic T-cell leukemia. Chromosomal rearrangements have been observed between this locus and at least two loci, the delta subunit of the T-cell antigen receptor gene and the LIM domain binding 1 gene. Alternatively spliced transcript variants have been described.
LIM domain only 1 (rhombotin 1)
, LIM domain only protein 1
, LIM only 1
, T-cell translocation protein 1
, cysteine-rich protein TTG-1
, LIM domain only protein 3
, LIM domain only 3
, neuronal-specific transcription factor DAT1
, dopamine-inducible LIM-domain transcription factor DAT1
, T-cell translocation gene 1
, rhombotin 1